Table 1

Within-subject treatment difference for liraglutide compared with crossover treatment with placebo on 24-h ABPM

VariableBaseline median (ICR)Treatment group liraglutide (1.8 mg) 21 days, (n = 17) LSMD from baseline (±SE)Treatment group placebo 21 days, (n = 17) LSMD from baseline (±SE)Treatment difference liraglutide (1.8 mg) vs. placebo LSMD (±SE), P value
SBP (mmHg)
 24 h130.45 (136.19, 127.10)+1.62 ± 2.04−0.72 ± 2.04+2.33 ± 1.67, P = 0.18
 Daytime133.07 (141.70)+1.68 ± 2.14−0.58 ± 2.14+2.25 ± 1.78, P = 0.23
 Nighttime122.73 (129.69, 118.58)+0.87 ± 2.64−0.83 ± 2.64+1.70 ± 2.77, P = 0.54
DBP (mmHg)
 24 h79.74 (83.05, 68.79)+3.39 ± 1.12−0.39 ± 1.12+3.78 ± 1.34, P = 0.01
 Daytime79.67 (85.44, 70.48)+3.66 ± 1.24+0.19 ± 1.24+3.48 ± 1.48, P = 0.03
 Nighttime71 (75.75, 63.98)+2.32 ± 1.46−1.44 ± 1.46+3.77 ± 1.74, P = 0.05
HR (bpm)
 24 h67.59 (86.17, 63)+7.39 ± 2.08+2.18 ± 2.08+5.21 ± 2.42, P = 0.05
 Daytime73.32 (89.68, 64.93)+6.51 ± 2.28+1.94 ± 2.27+4.57 ± 2.69, P = 0.11
 Nighttime63.25 (76.02, 58.53)+9.73 ± 1.77+2.39 ± 1.77+7.34 ± 2.38, P = 0.008
MAP (mmHg)
 24 h97.03 (100.32, 91.26)+1.71 ± 1.83−0.60 ± 1.83+2.31 ± 2.18, P = 0.30
 Daytime101.43 (103.09, 93.74)+2.65 ± 1.48−0.06 ± 1.48+2.71 ± 1.53, P = 0.10
 Nighttime89.57 (95.07, 84.56)−0.10 ± 1.53+1.21 ± 1.54−1.32 ± 2.18, P = 0.55
PP (mmHg)
 24 h54.62 (61.76, 46.88)−1.99 ± 1.36−0.76 ± 1.36−1.22 ± 1.33, P = 0.37
 Daytime54.75 (63.07, 47.42)−0.98 ± 0.94−1.77 ± 0.94+0.78 ± 1.33, P = 0.56
 Nighttime52.64 (60.12, 46.13)−1.45 ± 1.63+0.62 ± 1.63−2.07 ± 1.50, P = 1.19
  • Baseline data are presented as median (ICR), and the baseline-subtracted within-subject difference for 21-day liraglutide treatment compared with 21-day treatment with placebo are presented as LSMD ± SE. Boldface indicates statistical significance. ICR, interquartile range; LSMD, least squares mean difference; MAP, mean arterial pressure; PP, pulse pressure.